絞り込み

16533

広告

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.

著者 Sue S , Ogushi M , Arima I , Kuwashima H , Nakao S , Naito M , Komatsu K , Kaneko H , Tamura T , Sasaki T , Kondo M , Shibata W , Maeda S
Helicobacter.2017 Dec 21 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (230view , 0users)

Full Text Sources

The eradication rate of vonoprazan-based first-line triple therapy (combined with clarithromycin and amoxicillin) (V-AC) was reported to be 97.6% in patients with clarithromycin (CAM)-susceptible Helicobacter pylori in a phase III study, whereas our real-world, prospective, multicenter cohort study yielded an eradication rate <90%.
PMID: 29271026 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード